Bill Gross warns on gold momentum as regional bank stocks tumble
Oric Pharmaceuticals NASDAQ:ORIC Chief Financial Officer Dominic Piscitelli sold 11,000 shares of common stock on October 6, 2025, at prices ranging from $14.50 to $14.53, for a total of $159,718. The sale comes as the stock trades near its 52-week high of $14.93, having delivered an impressive 232% return over the past six months.
Piscitelli also exercised options to acquire 11,000 shares of Oric Pharmaceuticals’ common stock at a price of $4.36 per share, for a total value of $47,960. These options were related to shares that will expire on July 19, 2032. The transaction occurs amid strong analyst sentiment, with a highly bullish consensus rating of 1.17 on a scale where 1 represents a "Strong Buy."
Following these transactions, Piscitelli directly owns 48,317 shares of Oric Pharmaceuticals.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2025.
In other recent news, ORIC Pharmaceuticals has garnered attention from several analyst firms due to its promising cancer drug developments. Cantor Fitzgerald has reiterated its Overweight rating, suggesting that ORIC Pharmaceuticals is undervalued, particularly in light of its oral PRC2 inhibitor, ORIC-944, which is being developed for prostate cancer. Guggenheim initiated coverage with a Buy rating, highlighting the potential of ORIC-944 as a treatment for metastatic castration-resistant prostate cancer (mCRPC). Jefferies has also shown confidence by raising its price target for ORIC Pharmaceuticals to $23.00, maintaining a Buy rating, and noting the company’s focus on its ’944 mCRPC and ’114 NSCLC programs.
Additionally, Ladenburg Thalmann has initiated coverage with a Buy rating and a $15.00 price target, acknowledging the emerging profile of ORIC-944. In a strategic move, ORIC Pharmaceuticals has appointed Kevin Brodbeck as Chief Technical Officer, preparing for potential Phase 3 trials of its cancer treatment candidates ORIC-944 and enozertinib (ORIC-114) in 2026. These developments indicate a period of strategic growth and focus on ORIC’s cancer treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.